Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

NORML

MAY 26, 2020

Adverse events were mostly mild and resolved spontaneously. Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” The 1mg dose showed a significant pain decrease compared to the placebo.

Clinical Trials 248

Clinical Trials Chronic Pain Cannabinoids Patients 248

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 21, 2021

The treatment is designed to target nociplastic pain originating in the central nervous system through the neuroplasticity benefits of psilocybin. “Existing treatment options for fibromyalgia are often ineffective and show significant side effects,” said Daniel Clauw, M.D., San Diego, California–(Newsfile Corp.

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

NOVEMBER 17, 2021

There is one problem, Malaysia currently has no registered cannabis-based treatment. The National Pharmaceutical Regulatory agency (NPRA) approved Sativex in 2014 for patients experiencing muscle spasms and spasticity from multiple sclerosis. Importers would be required to hold permits and licenses. Sativex in Malaysia.

Research and Development 111

Research and Development Patients Treatment Pharmaceutical 111

CannaMD

FEBRUARY 19, 2020

Before getting to this news, let’s take a minute to review some of the prior research supporting marijuana for the treatment PTSD. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD. Need Your Medical Marijuana Card?

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Cannabis Law Report

JULY 24, 2021

This expansive patent would allow Mydecine to scale its coverage in drug development research in lieu of promising discoveries and FDA-approval progress for novel therapeutics, including granting Breakthrough Therapy Designation to MDMA for the treatment of PTSD in recent years. About Mydecine Innovations Group.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 10, 2021

Xpira Pharmaceuticals Inc. Xpira’s scientific team has undertaken the research and development of psychedelic drug Treatments and delivery systems for improved psychedelic-assisted psychotherapy, where legally permitted.

Research and Development 102

Research and Development Microdosing Pharmaceutical Education 102

Cannabis Law Report

JUNE 16, 2021

“Santé is a key partner to for Wake as they are a leading contract research organization (CRO) in Canada with expertise in advancing plant-based pharmaceutical products through various phases of clinical trial development. We are excited to explore the potential of emergent psychedelic therapies. ABOUT SANTÉ CANNABIS.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

MARCH 18, 2021

They needed a model for Alzheimer’s disease in order to effectively review cannabidiol (CBD) as a potential treatment. Unfortunately, both of these conditions result in cognitive decline and suffer from a lack of effective treatment. Why Aging Cats? What Did The Study Find?

CBD 95

CBD Research and Development Pets Treatment 95

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 10, 2021

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity.

eCommerce 61

eCommerce Research and Development Pharmaceutical Events 61

Cannabis Law Report

JULY 19, 2021

Philip Morris International recently offered £1 billion to buy Vectura Group PLC, the British pharmaceutical company that develops inhaled medical products. The global market for inhalation drug delivery devices is predicted to reach $17.6 billion by 2027. About RYAH Group, Inc.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Life Network

DECEMBER 6, 2022

Researchers at Oregon State University continue exploring whether cannabis is an effective treatment for COVID-19. Richard van Breemen, an Oregon State’s Global Hemp Innovation Center researcher, said that natural products like cannabis aren’t major research priorities for large pharmaceutical companies or federal drug research.

Treatment 115

Treatment Pharmaceutical Events Cannabinoids 115

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies.

Programs 100

Programs Data Events Collective 100

SpeedWeed

MARCH 13, 2021

Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . View original article.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. Then, something strange happened. In 2018, the U.S. Hundreds of other U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

The Joint Blog

DECEMBER 23, 2019

This is according to a new study published in the journal Current Pharmaceutical Biotechnology. No adverse events were reported in this study”, states the study. The treatment product was well-tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.”

Topical 49

Topical CBD Therapy Treatment 49

The Cannigma

OCTOBER 2, 2022

Additionally, nausea is a common side effect of cancer treatments, migraines, pregnancy, and more. In a 2020 study on cannabinoids and vomiting, researchers split the group into two: a group that took antiemetic pharmaceuticals and a group that took a CBD/ THC blend. Limonene is the dominant terpene in both kinds of mint.

Terpenes 113

Terpenes Strains THC Oil 113

Cannabis Law Report

JANUARY 16, 2020

Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. Tweet this. About Devonian. Devonian Health Group Inc.

Extraction 64

Extraction Pharmaceutical Research and Development Terpenes 64

Kind Meds (Cannabis Education Blog)

APRIL 23, 2019

While residential treatment is a well-known option for many, perhaps his month is the perfect time to discover how the use of another alternative can keep people away from alcohol. In some cases, it may be more effective than traditional treatment. Most treatment options include the ultimate goal of abstaining from alcohol use.

Treatment 40

Treatment Pharmaceutical Events Conditions 40

Cannabis Law Report

JULY 28, 2021

InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. The sol-gel technology is designed to deliver pharmaceutical compounds as a liquid at room temperature which becomes a gel at body temperature. About atai Life Sciences. atai – Investor Contact: Greg Weaver.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. Here are some examples of the marijuana panels that voters are able to select from: .

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

OCTOBER 13, 2021

Drug-assisted psychotherapy combines drug and psychological treatments to leverage the benefits of each for a superior outcome. Clearmind Medicine will host ‘Psychedelics for Alcoholism,’ a free, live virtual event highlighting new potential treatments for alcohol use disorder and binge drinking, on Oct. Register here.

Medicine 52

Medicine Research and Development Therapy Events 52

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. and 43 international patent-pending applications, which provide patent protection for both PhAROS™, its proprietary drug discovery engine, and its novel, plant-inspired combination drugs for the treatment of more than 65 serious medical conditions.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JULY 7, 2021

is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. KetamineOne Capital Limited (formerly Myconic Capital Corp.)

Research and Development 98

Research and Development Treatment Therapy Banking 98

The Joint Blog

FEBRUARY 15, 2020

Researchers reported no serious adverse events resulting from the discontinuation of CBD. They found that “In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.” Thirty volunteers were randomized to receive 750?mg weeks (Part 1) followed by 2?

CBD 54

CBD Treatment Events Epilepsy 54